Northwest Financial Statements From 2010 to 2024
| NWBO Stock | USD 0.47 0.01 2.08% |
Check Northwest Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Northwest main balance sheet or income statement drivers, such as , as well as many exotic indicators such as . Northwest financial statements analysis is a perfect complement when working with Northwest Biotherapeutics Valuation or Volatility modules.
Northwest |
Northwest Biotherapeutics OTC Stock Return On Asset Analysis
Northwest Biotherapeutics' Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Northwest Biotherapeutics Return On Asset | -1.26 |
Most of Northwest Biotherapeutics' fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Northwest Biotherapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Based on the latest financial disclosure, Northwest Biotherapeutics has a Return On Asset of -1.2576. This is 85.63% lower than that of the Biotechnology sector and 94.67% lower than that of the Health Care industry. The return on asset for all United States stocks is notably higher than that of the company.
Northwest Biotherapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Northwest Biotherapeutics's current stock value. Our valuation model uses many indicators to compare Northwest Biotherapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Northwest Biotherapeutics competition to find correlations between indicators driving Northwest Biotherapeutics's intrinsic value. More Info.Northwest Biotherapeutics is considered to be number one stock in return on asset category among related companies. It is considered to be number one stock in profit margin category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Northwest Biotherapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Northwest Biotherapeutics' OTC Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Northwest Biotherapeutics' earnings, one of the primary drivers of an investment's value.About Northwest Biotherapeutics Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Northwest Biotherapeutics income statement, its balance sheet, and the statement of cash flows. Northwest Biotherapeutics investors use historical funamental indicators, such as Northwest Biotherapeutics's revenue or net income, to determine how well the company is positioned to perform in the future. Although Northwest Biotherapeutics investors may use each financial statement separately, they are all related. The changes in Northwest Biotherapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Northwest Biotherapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Northwest Biotherapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Northwest Biotherapeutics. Please read more on our technical analysis and fundamental analysis pages.
Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company was founded in 1996 and is headquartered in Bethesda, Maryland. Northwest Bioth operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 19 people.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Northwest Biotherapeutics Correlation against competitors. Note that the Northwest Biotherapeutics information on this page should be used as a complementary analysis to other Northwest Biotherapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Complementary Tools for Northwest OTC Stock analysis
When running Northwest Biotherapeutics' price analysis, check to measure Northwest Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Northwest Biotherapeutics is operating at the current time. Most of Northwest Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Northwest Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Northwest Biotherapeutics' price. Additionally, you may evaluate how the addition of Northwest Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Transaction History View history of all your transactions and understand their impact on performance |